Aktueller Stand der immunsuppressiven Therapie unter besonderer Berücksichtigung des transplantierten Patienten in der Chirurgie

Die Zahl organtransplantierter Patienten ist kontinuierlich steigend, sodass auch niedergelassene Ärzte und Ärzte in nicht transplantierenden Krankenhäusern und in Praxen zunehmend mit der Betreuung transplantierter Patienten konfrontiert werden.

• Quellenangaben

• 1 Hahn H, Falke D, Kaufmann S, Ullmann U. Medizinische Mikrobiologie und Infektiologie. 4. Aufl.. Berlin, Heidelberg, New York: Springer; 2000
• 2 Herdegen T. Kurzlehrbuch Pharmakologie. Stuttgart: Thieme; 2008
• 3 Pezzutto A, Ulrichs T, Burmester GR. Taschenatlas der Immunologie. 2.Aufl.. Stuttgart: Thieme; 2006
• 4 Novartis Pharma Stein AG. Zortress (Everolimus) Highlights of prescribing Information. 2013 Im Internet: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021560s006lbl.pdf Stand: 23.03.2015
• 5 Nashan B. Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs 2002; 11: 1845-1857
• 6 Nashan B, Gaston R, Emery V et al. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation 2012; 93: 1075-1085
• 7 Novartis P. Fachinformation Certican (Everolimus). 2012.
• 8 Trotter JF, Lizardo-Sanchez L. Everolimus in liver transplantation. Curr Opin Organ Transplant 2014; 19: 578-582
• 9 Azzola A, Havryk A, Chhajed P et al. Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. Transplantation 2004; 77: 275-280
• 10 Nashan B, Citterio F. Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature. Transplantation 2012; 94: 547-561
• 11 Nashan B. mTOR inhibitors and their role in modern concepts of immunosuppression. World J Surg 2014; 38: 3199-3201
• 12 Koch M, Kantas A, Ramcke K et al. Surgical complications after kidney transplantation: Different impacts of immunosuppression, graft function, patient variables, and surgical performance. Clin Transplant 2015; 29: 252-260
• 13 Schwarz L, Cauchy F, Conti F et al. Preliminary report of major surgery in liver transplant recipients receiving m-TOR inhibitors without therapeutic discontinuation. World J Surg 2014; 38: 3193-3198
• 14 U.S. Food and Drug Administration. Sandimmune (Cyclosporine, USP) Injection, Oral solution and Gelatin Capsules. 2013 Im Internet: http://www.fda.gov/safety/medwatch/safetyinformation/ucm319403.htm Stand: 23.03.2015
• 15 Astellas Pharma US, Inc. Tacrolimus (Prograf). Highlights of prescribing information. 2011 Im Internet: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050708s036s037,050709s028s030lbl.pdf Stand: 23.03.2015
• 16 Bundesministerium für Gesundheit. Richtlinie über die Verordnung von Arzneimitteln in der vertragsärztlichen Versorgung. Abschnitt M § 40 18.09.2014.
• 17 Sgourakis G, Dedemadi G. Corticosteroid-free immunosuppression in liver transplantation: an evidence-based review. World J Gastroenterol 2014; 20: 10703-10714
• 18 Klintmalm GB, Feng S, Lake JR et al. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. Am J Transplant 2014; 14: 1817-1827
• 19 De Simone P, Nevens F, De Carlis L et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant 2012; 12: 3008-3020
• 20 Rote Liste Service GmbH (Herausgeber und Verlag). Rote Liste 2014 – Arzneimittelverzeichnis für Deutschland (einschließlich EU-Zulassungen und bestimmter Medizinprodukte). 54. Ausgabe. Frankfurt/Main.
• 21 AQUA – Institut für angewandte Qualitätsförderung und Forschung im Gesundheitswesen GmbH. Benchmark-Report 2012. Im Internet: http://www.sqg.de Stand: 31.03.2015
• 22 Opelz G, Döhler B. Collaborative Transplant Study. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation 2009; 87: 795-802
• 23 Nashan B, Curtis J, Ponticelli C et al. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation 2004; 78: 1332-1340
• 24 Vitko S, Margreiter R, Weimar W et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005; 5: 2521-2530
• 25 Webster AC, Lee VW, Chapman JR et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006; 81: 1234-1248
• 26 Prince O, Savic S, Dickenmann M et al. Risk factors for polyoma virus nephropathy. Nephrol Dial Transplant 2009; 24: 1024-1033
• 27 Habicht A, Broker V, Blume C et al. Increase of infectious complications in ABO-incompatible kidney transplant recipients–a single centre experience. Nephrol Dial Transplant 2011; 26: 4124-4131
• 28 Oettl T, Halter J, Bachmann A et al. ABO blood group-incompatible living donor kidney transplantation: a prospective, single-centre analysis including serial protocol biopsies. Nephrol Dial Transplant 2009; 24: 298-303
• 29 Cai J, Terasaki PI, Bloom DD et al. Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction. Transplantation 2004; 78: 919-924
• 30 Knechtle SJ, Pascual J, Bloom DD et al. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. Am J Transplant 2009; 9: 1087-1098
• 31 Roodnat JI, Hilbrands LB, Hene RJ et al. 15-year follow-up of a multicenter, randomized, calcineurin inhibitor withdrawal study in kidney transplantation. Transplantation 2014; 98: 47-53
• 32 Naesens M, Salvatierra O, Benfield M et al. Subclinical inflammation and chronic renal allograft injury in a randomized trial on steroid avoidance in pediatric kidney transplantation. Am J Transplant 2012; 12: 2730-2743
• 33 Sarwal MM, Ettenger RB, Dharnidharka V et al. Complete steroid avoidance is effective and safe in children with renal transplants: a multicenter randomized trial with three-year follow-up. Am J Transplant 2012; 12: 2719-2729
• 34 Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation 2010; 89: 1-14
• 35 Vincenti F, Blancho G, Durrbach A et al. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol 2010; 21: 1587-1596
• 36 Vincenti F, Larsen C, Durrbach A et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770-781
• 37 Charpentier B, Medina Pestana JO, Del C Rial M et al. Long-term exposure to belatacept in recipients of extended criteria donor kidneys. Am J Transplant 2013; 13: 2884-2891
• 38 Rostaing L, Vincenti F, Grinyo J et al. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant 2013; 13: 2875-2883